ResearcherThe University of OsakaActive in the last 2 years
Katsuhiko Sato
Matched on ORCID iD 0000-0001-6288-9106; OpenAlex author ID A5029798786. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers
Papers 6
- The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia. Co-author DOI 10.1016/j.pan.2023.11.005↗
- The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis. Co-author DOI 10.1038/s41598-024-62498-x↗
- Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity. Co-author DOI 10.1186/s13046-023-02831-w↗
- Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Co-author DOI 10.1111/cas.15569↗
- Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Co-author DOI 10.1097/mpa.0000000000001521↗
- Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. Co-author DOI 10.1371/journal.pone.0235573↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teppei Yoshioka · 6 shared papers, 2020–2024 · strength 0.78
- Paper The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis. DOI 10.1038/s41598-024-62498-x↗
- Paper The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary… DOI 10.1016/j.pan.2023.11.005↗
- Paper Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of antican… DOI 10.1186/s13046-023-02831-w↗
- Tetsuo Takehara · 6 shared papers, 2020–2024 · strength 0.78
- Paper The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis. DOI 10.1038/s41598-024-62498-x↗
- Paper The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary… DOI 10.1016/j.pan.2023.11.005↗
- Paper Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of antican… DOI 10.1186/s13046-023-02831-w↗
- Junya Okabe · 2 shared papers, 2023–2024 · strength 0.30
- Paper The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary… DOI 10.1016/j.pan.2023.11.005↗
- Paper Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of antican… DOI 10.1186/s13046-023-02831-w↗
- Kenji Ikezawa · 2 shared papers, 2020–2024 · strength 0.26
- Paper The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary… DOI 10.1016/j.pan.2023.11.005↗
- Paper Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesio… DOI 10.1097/mpa.0000000000001521↗
- Takuo Yamai · 2 shared papers, 2020 · strength 0.20
- Paper Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesio… DOI 10.1097/mpa.0000000000001521↗
- Paper Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. DOI 10.1371/journal.pone.0235573↗
- Tadashi Kegasawa · 1 shared paper, 2024 · strength 0.16
- Kengo Matsumoto · 1 shared paper, 2024 · strength 0.16
- Motohiro Hirao · 1 shared paper, 2024 · strength 0.16
- Masaya Higashiguchi · 1 shared paper, 2023 · strength 0.14
- Kazuma Daiku · 1 shared paper, 2023 · strength 0.14
- Hidetoshi Eguchi · 1 shared paper, 2023 · strength 0.14
- Makiko Urabe · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.